The latest efficacy of dabrafenib mesylate has been clarified

Dabrafenib (Dabrafenib) is a targeted therapy drug commonly used to treat advanced or metastatic melanoma (skin cancer) with positive BRAF V600E/K gene mutations. However, specific efficacy may vary based on individual differences, disease stage, and the combination of other treatments, and some patients may be resistant or ineffective.

Based on the latest clinical trial data and research, dabrafenib mesylate has achieved significant efficacy in treating this type of melanoma. In most patients, dabrafenib can prolong progression-free survival and overall survival. Specifically, dabrafenib can inhibit the mutational activity of the BRAF gene, thereby blocking cell proliferation and melanoma growth. It can reduce tumor size and cause partial or complete tumor shrinkage in some patients. In addition, dabrafenib may also cause some side effects, such as skin inflammation, rash, fever, etc.

The original drug of dabrafenib is relatively expensive and has been covered by medical insurance since it was launched in China. Currently only eligible patients are reimbursed. The price of each box of 50mg*120 capsules may be around around 10,000. The Turkish version of the original drug Dabrafenib sold overseas, Specifications 75mg*120 capsules, may cost around 10,000 per box (the price may fluctuate due to exchange rates). There are also relatively cheap generics of dabrafenib sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, Specifications produced by Laos Pharmaceutical Factory The price of 75mg*120 tablets per box may be more than 4,000 yuan (the price may fluctuate due to exchange rates).